Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not have an impact on its operating profit for 2025. “Sanofi is picking up the ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $9, saying recent gains in the shares have overrun a still uncertain ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Trade Name in the U.S. The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA). Authorized Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given ...

Outside of the U.S., the Novavax COVID-19 vaccine, named Nuvaxovid, has received emergency use authorization in more than 40 countries and is listed for emergency use by the World Health Organization.

The commission authorized Nuvaxovid after a recommendation issued on Monday by the European Medicines Agency. In a statement, Novavax said that it expected initial doses to arrive in Europe in ...

Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses.